Cambridge-based Endomag, a fast-growing technology businesses, has won the Queen’s Award for Enterprise: International Trade.
Now in its 55th year, the Queen’s Awards for Enterprise are the most prestigious business awards in the country, celebrating the UK’s most innovative and fast-growing companies.
Commenting on the award, Endomag’s Chief Executive Officer, Eric Mayes said: “We feel so privileged to be recognised with a prestigious Queen’s Award for our hard work this year in expanding into other markets. Our technologies have so far been able to help over 130,000 women in over 40 countries. I’m so excited to continue to explore how our magnetic technologies can make a difference for people living with breast cancer.”
It is the second time that Endomag has been recognised by these awards, having received the Queen’s Award for Enterprise: Innovation in 2018. Winning a second Queen’s Award in such a short period of time is rare and cements Endomag’s reputation as one of the leading medical device technology companies in the UK.
Originally founded in 2007 by professors at University College London (UCL) and the University of Houston, Endomag’s technology harnesses the power of magnetics to enable a better standard of cancer care.
The heart of the company’s technology platform is the Sentimag® localisation system. The system features a probe which works like a metal detector, and when placed near the skin’s surface is used to detect Endomag’s magnetic seed (Magseed®) for accurately removing cancer, or liquid tracer (Magtrace®), to identify lymph nodes that a cancer may have spread to for more accurate analysis.
Since launching its products in the UK, the company has established an impressive trading footprint and also expanded into North America, and has continued to enter new markets in Europe, Asia and Australasia. Its innovative medical technologies are manufactured in the UK and shipped around the world. So far, Endomag’s technologies have helped over 130,000 women from over 40 countries receive more precise and less invasive cancer treatment.